- Division of Translational and Clinical Sciences – DTCS
- Oncology 2 – Translational Clinical – OTC
- Study Section:
- Developmental Therapeutics – DT
Dr. Nicholas Donato received his Ph.D. in biochemistry from the University of California in Riverside focusing on the study of polyamine metabolism. He continued training at MD Anderson Cancer Center in Houston, Texas, and rose through the ranks to associate professor studying cytokine signal transduction and post-translation protein modification and their role in cancer therapeutic responsiveness. Before joining NIH, Dr. Donato was a faculty member at the University of Michigan in Ann Arbor, where he worked in the field of deubiquitinases as cancer targets and developed several inhibitors that have been licensed for clinical development. He has authored many publications, holds several patents and his research was supported by NIH, DOD and several foundations.